Compounds & interventions

Retatrutide

Medicine & Biotech · covered by 10 outlets this week · tracked since 2026-10-27

Press: 6 mainstream 16 specialist 7 independent outlet-days

Background

Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors. Wikipedia ↗

Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.

Coverage